Table 2 Number of DEGs involved in selected KEGG pathways at each age group. Values in the parentheses are Q-values of pathway enrichment test, and significant Q-values (< 0.1) are marked witha
Pathways | Month 2 | Month 4 | Month 6 | Month 8 |
|---|---|---|---|---|
NF-κB signaling | 7 (9.69E-03a) | 21 (8.74E-03a) | 18 (2.44E-01) | 24 (2.83E-03a) |
cytokine-cytokine receptor interaction | 11 (1.86E-02a) | 42 (1.82E-02a) | 53 (1.07E-02a) | 49 (4.68E-03a) |
Lysosome | 4 (4.73E-01) | 37 (3.96E-08a) | 40 (1.13E-06a) | 41 (8.58E-09a) |
Alzheimer’s disease | 3 (7.53E-01) | 45 (1.41E-08a) | 56 (2.20E-10a) | 39 (1.51E-04a) |
Parkinson’s disease | 0 | 30 (2.75E-04a) | 42 (3.43E-07a) | 26 (2.51E-02a) |
Huntington’s disease | 0 | 33 (8.74E-03a) | 47 (8.59E-05a) | 27 (3.54E-01) |
Oxidative phosphorylation | 0 | 37 (1.41E-08a) | 47 (4.71E-11a) | 33 (3.82E-05a) |
HIF-1 signaling pathway | 3 (6.34E-01) | 25 (1.12E-03a) | 25 (2.51E-02a) | 23 (2.26E-02a) |
Phagosome | 3 (7.91E-01) | 31 (1.89E-03a) | 45 (2.40E-04a) | 43 (5.11E-05a) |